Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T20:35:40.785Z.
Calculation as of: 2026-10-06T20:35:40.785Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3c83d1468e5e3921618bd37e367f41e2e7287b0e28e44d51d30477b87a45d5ec
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Baird Medical Investment Holdings Limited
Market Cap
$32.93M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$33.29M
EV/Sales Ratio
0.20x
TTM Avg
15.56x
3Y Avg
19.81x
5Y Avg
321.73x
Market Cap
$33.63M
EV/Sales Ratio
4.07x
TTM Avg
4.11x
3Y Avg
4.50x
5Y Avg
18.25x
Market Cap
$31.52M
EV/Sales Ratio
0.39x
TTM Avg
0.41x
3Y Avg
0.37x
5Y Avg
0.39x
Market Cap
$31.11M
EV/Sales Ratio
0.43x
TTM Avg
0.48x
3Y Avg
0.66x
5Y Avg
0.78x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Baird Medical Investment Holdings Limited (BDMD) | $32.93M | N/A | N/A | N/A | N/A |
| Nephros, Inc. (NEPH)vs › | $32.79M | 1.40x | 2.22x | 1.81x | 1.98x |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.29M | 0.20x | 15.56x | 19.81x | 321.73x |
| HeartBeam, Inc. (BEAT)vs › | $32.42M | N/A | N/A | N/A | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.61M | N/A | N/A | N/A | N/A |
| Scilex Holding Company (SCLX)vs › | $33.63M | 4.07x | 4.11x | 4.50x | 18.25x |
| Nortech Systems Incorporated (NSYS)vs › | $31.52M | 0.39x | 0.41x | 0.37x | 0.39x |
| Elutia Inc (ELUT)vs › | $34.35M | 2.08x | 1.98x | 3.00x | 2.66x |
| Accuray Incorporated (ARAY)vs › | $31.11M | 0.43x | 0.48x | 0.66x | 0.78x |
| CervoMed Inc. (CRVO)vs › | $30.92M | 26.23x | 97.17x | 97.17x | 97.17x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
